Corporate physiotherapy services are used by hospitals and nursing homes to treat people with a range of health conditions, from asthma and hypertension to osteoarthritis and cancer.
But it is also being used by the pharmaceutical industry, with drugs being prescribed for a range the same symptoms that are seen in patients with cancer.
The report by the University of Sydney, which was commissioned by the Australian Competition and Consumer Commission (ACCC), also found that the majority of patients who needed these treatments were in poorer health than the average person.
The findings are contained in a report to be released this week by the ACCC.
The company that has a monopoly on the treatment is the US-based company Miller & Nash.
Its main competitors are Johnson &.
and Amgen, which has a similar product.
But the Miller & amp; Nash is owned by Johnson &amgt.
Dr Steve Jankowiak, a consultant in the area of health care and human behaviour at the University.
He says the findings show that Miller &amlt is a monopolistic company and that the industry should be encouraged to change its business model.
“It’s the monopoly issue.
The monopoly issue is that Miller&nash is very powerful and that’s not going to change,” he says.
He points out that the Miller<ns new drug is not available in Australia.
Dr Janko says that it’s important for people to know that the current system is failing.
“If you look at the big companies, they don’t care about the people with cancer and they don-t care about people with chronic diseases.
They don’t know anything about the patients,” he said.
“They don’t do a lot of research and they do everything on their own.”
Dr Jick says that the situation is similar for the pharmaceutical sector.
“The monopoly is that the people who need these treatments are very wealthy, so they don”t care much about what happens to people who are really ill.
“I think it is a very cynical thing to say, but that’s what they’re doing,” he adds.
Dr. Jankyak says that he hopes the ACCS will launch a review into whether the monopoly has changed or not.
“There is a need for some transparency.
We need some accountability.
We want to know how the system works,” he told the ABC.
“This monopoly is not going away.”
He says that some of the changes that are happening are good, but the industry needs to take more responsibility for its operations.
“We need to get better at communicating to patients, but we also need to do a better job at getting better information for them,” he added.